Login to Your Account



Dainippon Sumitomo Gets Dibs on Cancer Candidate in Japan

By Catherine Shaffer


Friday, April 8, 2011
Dainippon Sumitomo Pharma Co. Ltd. (DSP) bested a field of a dozen interested companies to license a small-molecule oncology drug, BBI608, from Boston Biomedical Inc. DSP will pay $15 million up front, with the potential for up to $155 million more in development costs and milestones. The agreement covers all oncology indications in Japan, and exclusive right of negotiation for the drug in the U.S. and Canada.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription